Transgene

Transgene FCF per Share

The Free Cash Flow per Share of Transgene (TNG.PA) as of Oct 8, 2026 is -0.23 EUR. In the previous year, Free Cash Flow per Share was -0.37 EUR — a change of -38.54% (higher).

FCF per Share

-0.23EUR

YoY

-38.54%

Last updated:

Free Cash Flow per Share of Transgene is 2024 -0.23 EUR. Free Cash Flow per Share of Transgene was 2023 -0.37 EUR. It decreases by -38.54% higher compared to the previous year.

The Transgene FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2017
-0.56 EUR
Jan 1, 2018
-0.47 EUR
Jan 1, 2019
-0.29 EUR
Jan 1, 2020
-0.35 EUR
Jan 1, 2021
-0.29 EUR
Jan 1, 2022
-0.22 EUR
Jan 1, 2023
-0.37 EUR
Jan 1, 2024
-0.23 EUR
The Transgene FCF per Share history
YEARFCF per ShareYoY
-0.23EUR-38.54%
-0.37EUR+69.42%
-0.22EUR-24.90%
-0.29EUR-17.24%
-0.35EUR+19.57%
-0.29EUR-36.69%
-0.47EUR-17.20%
-0.56EUR-3.88%
-0.59EUR-49.39%
-1.16EUR-17.71%
-1.40EUR—
Access this data via the Eulerpool API
Get Free API Key

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Free Cash Flow per Share of Transgene is -0.23 EUR in 2024.

Free Cash Flow per Share of Transgene changed from -0.37 EUR to -0.23 EUR, representing a -38.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Transgene since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API
Get Free API Key

Cash Flow — Transgene

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Transgene